High materiality7/10
Cantor Fitzgerald Reiterates Overweight Rating on Quince Therapeutics Inc. (QNCX)
Why it may matterVerify against the original reporting
very_bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Cantor Fitzgerald reiterates overweight rating with a target of $70. Current price is $32.91; price has risen by $5.65 since the signal.
- Target: $70
- Posted price: $32.91
- Analyst: Olivia Brayer Saunders
- Analyst firm: Cantor Fitzgerald
- Price change since signal: +$5.65
Key facts
- 01
Target: $70
- 02
Posted price: $32.91
- 03
Analyst firm: Cantor Fitzgerald
- 04
Analyst: Olivia Brayer Saunders
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.